

Near Infrared Spectrometry (NIRS) monitoring is much simpler than MEP's

Carlos H Timaran, MD

Chief, Endovascular Surgery

Sam H. Phillips Jr MD Distinguished Chair in Surgery

Professor of Surgery

Extraordinary times




Disclosure



- Honoraria / Consultant / Research
 - W.L. Gore
 - Cook Medical Inc
- Some devices presented here are investigational and have not been approved by the FDA
- Acknowledgement
 - Gustavo Oderich, MD
Mayo Clinic, Rochester, MN, USA
 - Darren Schneider, MD
Weill Cornell – New York-Presbyterian, New York, NY, USA

Spinal cord ischemia (SCI)




- Spinal cord ischemia (SCI) is a devastating complication after open and endovascular repair of thoracoabdominal aortic aneurysms (TAAA)
- Spinal drains are routinely used to ameliorate the frequency and severity of SCI, but their use may result in inherent morbidity and mortality



Spinal Cord Perfusion



Paraspinal musculature



Oderich 2017

IONM (MEP & SSEP) for F/BEVAR

Clinical Investigation

Neuromonitoring, Cerebrospinal Fluid Drainage, and Selective Use of Iliofemoral Conduits to Minimize Risk of Spinal Cord Injury During Complex Endovascular Aortic Repair


Peter V. Banga, MD^{1,2}, Gustavo S. Oderich, MD¹, Leonardo Reis de Souza, MD^{1,3}, Jan Hofer, RN¹, Meaghan L. Cazares Gonzalez, R.NCS.T⁴, Juan N. Pulido, MD⁵, Stephen Cha, MS⁶, and Peter Gloviczki, MD¹

JOURNAL OF
ENDOVASCULAR
THERAPY

Journal of Endovascular Therapy
2016, Vol. 23(1) 139–149
© The Author(s) 2015
Reprints and permissions:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1526602815620898
www.jevt.org
SAGE





- 49 pts (90%, TAAAs) → All CSF drainage
- SCI, 3 pts (6%)
- 63% → >75% ↓ MEP/SSEP amplitude
- MEP/SSEP back to baseline but in 1 pt

J Endovasc Ther. 2016;23:139-49



Near InfraRed Spectroscopy (NIRS)

- NIRS measures transcutaneous tissue oxygenation
- Paraspinous muscle O₂ saturation is a reflection of spinal cord collateral network perfusion



Oderich 2017

NIRS Advantages

- Non-invasive
- Widely available and low cost
- Lower extremity ischemia and anesthetics don't interfere with monitoring
- No need for specialized interpretation
 - Postoperative monitoring & early changes detection





Near-infrared Spectroscopy Monitoring of the Collateral Network Prior to, During, and After Thoracoabdominal Aortic Repair: A Pilot Study

C.D. Etz ^{a,b,*}, K. von Aspern ^{a,d}, S. Gudehus ^c, M. Luehr ^a, F.F. Girrbach ^a, J. Ender ^c, M. Borger ^a, F.W. Mohr ^a

^a Department of Cardiac Surgery, University of Leipzig, Heart Center Leipzig, Saxony, Germany

^b Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, NY, USA

^c Department of Anesthesiology, University of Leipzig, Heart Center Leipzig, Saxony, Germany



- Aortic cross clamp and CPB change lumbar CN perfusion
- SCI associated with greater reduction in saturations

Etz, et al. *Eur J Vasc Endovasc Surg* 2013

Spinal Drain Complications

Cerebrospinal fluid drainage complications during first stage and completion fenestrated-branched endovascular aortic repair

Jussi M. Kärkkäinen, MD, PhD,^a Nolan C. Cirillo-Penn, MD,^a Indrani Sen, MD,^a Emanuel R. Tenorio, MD, PhD,^a William J. Mauermann, MD,^b George D. Gilkey, MD,^b Timothy J. Kaufmann, MD, MS,^c and Gustavo S. Oderich, MD,^a Rochester, Minn

187 pts with 240 endovascular procedures with CSF drain

CSFD-related complications	n	% / patients
Any complication	21	10
Severe	8	4
Moderate	9	5
Minor	4	1

Spinal cord protection protocol:

Elective Fenestrated and Branched Endovascular Thoraco-abdominal Aortic Repair with Supraceliac Sealing Zones and without Prophylactic Cerebrospinal Fluid Drainage: Early and Medium-term Outcomes

Maciej T. Juszcak, Anna Murray, Andreas Koutsoumpelis, Massimo Vezzosi, Jorge Mascaro, Martin Claridge, Donald I. Adam

Table 1. In house spinal cord protection protocol


Stop antihypertensive medication three days before operation
Preserve antegrade perfusion of left subclavian and at least one hypogastric artery
Minimise embolisation during graft manipulation
Minimise lower limb ischaemia—reperfusion injury (early removal of delivery sheaths, separate sheaths for target vessel cannulation, pre-loaded devices)
Minimise intra-operative blood loss and post-operative risk of GI haemorrhage (PPI)
Staged procedures where appropriate (based on extent of coverage and spinal collateral network)
Maintain MAP > 80 mmHg
Patient recumbent at 30° for 36 h minimum
CVP < 15 mmHg
Maintain oxygen delivery for entire hospital admission (Hb > 10, pO ₂ > 9, SaO ₂ > 95%)
Correct any coagulopathy (aim for platelet count > 100, PTR < 1.5)
Gradual mobilisation from 48 h and gradual re-introduction of antihypertensives
No prophylactic CSF drainage

167 pts with proximal SC \geq 40mm without prophylactic SCF drain
SCI 2 (1.2%) $p=.001$ [OR =19.9]


Eur J Vasc Endovasc Surg. 2019 May;57(5):639-648

SCI after TAAA EVAR

- The need for or the effectiveness of spinal drains for TAAA EVAR has not been demonstrated.
- Initial experience of spinal cord protection without the routine use of spinal drains during TAAA EVAR using NIRS & IONM



Physician-sponsored Investigational Device Exemption (IDE)

 **DEPARTMENT OF HEALTH & HUMAN SERVICES** Public Health Service
Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-0609
Silver Spring, MD 20993-0002

July 16, 2014


Carlos H. Timaran, M.D.
Associate Professor of Surgery
Chief of Endovascular Surgery
Division of Vascular/ Endovascular surgery
University of Texas Southwestern Medical Center
5959 Harry Hines Blvd POB 1 Ste. 6.620
Dallas, TX, 75390-9157

Re: G140108
Trade/Device Name: Cook Fenestrated Custom Made Device (CMD)
Dated: June 9, 2014
Received: June 18, 2014
CMS Category: B4
Annual Report Due: One Year from the Date of This Letter

Dear Dr. Timaran:

The Food and Drug Administration (FDA) has reviewed your Investigational Device Exemption (IDE) application regarding your research study that is considered a clinical investigation (Clinical Outcomes and Radiation Safety after Endovascular Repair of Complex Abdominal Aortic Aneurysms using Custom-Made Devices) of a significant risk device. FDA has determined you have provided sufficient data to support initiation of a human clinical study; this means that there are no subject protection concerns that preclude initiation of the investigation. Your application is therefore approved, and you may begin your investigation at the institution enrolled after you have obtained institutional review board (IRB) approval and submitted certification of IRB approval to FDA. Your investigation is limited to 1 institution and 150 subjects.

certification of IRB approval to FDA. Your investigation is limited to 1 institution and 150 subjects. Your application is therefore approved, and you may begin your investigation at the institution enrolled after you have obtained institutional review board (IRB) approval and submitted certification of IRB approval to FDA. Your investigation is limited to 1 institution and 150 subjects.



IONM (MEP & SSEP) + NIRS for F/BEVAR

Clinical Investigation


Neuromonitoring, Cerebrospinal Fluid Drainage, and Selective Use of Iliofemoral Conduits to Minimize Risk of Spinal Cord Injury During Complex Endovascular Aortic Repair

Peter V. Banga, MD^{1,2}, Gustavo S. Oderich, MD¹, Leonardo Reis de Souza, MD^{1,3}, Jan Hofer, RN¹, Meaghan L. Cazares Gonzalez, R.NCS.T⁴, Juan N. Pulido, MD⁵, Stephen Cha, MS⁶, and Peter Gloviczki, MD¹

JOURNAL OF
ENDOVASCULAR
THERAPY

Journal of Endovascular Therapy
2016, Vol. 23(1) 139-149
© The Author(s) 2015
Reprints and permissions:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1526602815620898
www.jevt.org
SAGE


- No preop CSF drains
- CSF drains only for persistent NIRS &/or MEP deficits or symptoms
- Selective CSF drains for partial CN
- PQ access + early revasc




34 patients enrolled

**All patients had IONM & NIRS (48 hrs)
selective spinal CSF drainage**

**10 Extent 4
TAAA (29%)**




**24 Extent 1-3
TAAA (71%)**



Staged repair for all type I-III TAAAs

Device design





Off-the-shelf
(CMD/Cook t-Branch®)

$n = 7$ (20%)
 3.8 ± 0.6
vessels/patient



CMDs
*Fenestrations or
branches*

$n = 27$ (80%)
 3.8 ± 0.5 vessels/patient




NIRS + IONM & Selective Spinal Drain Use

- 34 patients (73%, male)
- 80% → >75% ↓ MEP/SSEP amplitude
- No NIRS drop >20% in any patient (48 hrs)
- MEP/SSEP back to baseline but in 1 pt → Spinal drain placed → neuro intact



IONM & Selective Spinal Drain Use

- One 30-day death (3%)
- Spinal CSF drain placed in 3 pts (9%)
 - 1 IOP for sustained ↓ MEP/SSEP
 - 2 preemptively (HA occlusion, deficit after 1st stage)
 - Paraplegia in 1 pt (3%) on POD 7 resolved with CSF drainage (DAPT)



Conclusions

- F-BEVAR for TAAAs can be performed with low mortality and minimal risk of SCI without the need of routine spinal drains
- A standardized protocol that relies on perioperative maintenance of adequate arterial pressure is required.
- The use of NIRS (IONM) should be considered investigational
- Preliminary clinical data suggests NIRS may be a useful adjunct to monitor spinal cord collateral network perfusion during open TAAA repair
- Future studies are required to define the role and need of spinal drains for thoracoabdominal EVARs

